New drug shows promise for fatty liver disease in early trial
NCT ID NCT06104319
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This study tested a single dose of the experimental drug GSK4532990 in 61 adults with NASH, a type of fatty liver disease. Researchers measured how the drug moves through the body and affects liver proteins, while also checking for safety. The goal is to see if the drug can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Chula Vista, California, 91911, United States
-
GSK Investigational Site
Montclair, California, 91763, United States
-
GSK Investigational Site
San Diego, California, 91911, United States
-
GSK Investigational Site
San Diego, California, 91942, United States
-
GSK Investigational Site
Brandon, Florida, 33511, United States
-
GSK Investigational Site
Miami, Florida, 33155, United States
-
GSK Investigational Site
Miami, Florida, 33173, United States
-
GSK Investigational Site
Miami Lakes, Florida, 33014, United States
-
GSK Investigational Site
Indianapolis, Indiana, 46202, United States
-
GSK Investigational Site
El Dorado, Kansas, 67042, United States
-
GSK Investigational Site
Marrero, Louisiana, 70072, United States
-
GSK Investigational Site
Austin, Texas, 78745, United States
-
GSK Investigational Site
San Antonio, Texas, 78215, United States
-
GSK Investigational Site
San Antonio, Texas, 78240, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK4532990
What this could lead to
If successful, this could point toward a treatment for non-alcoholic steatohepatitis (NASH), a serious liver disease.
What could go wrong
This is an early-phase study with only 61 participants, so results may not confirm effectiveness or safety for wider use. The drug may not improve liver health.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.